AXIOS June 10, 2024
The outlook for the latest experimental drug shown to delay Alzheimer’s disease will come into focus Monday, when Food and Drug Administration advisers review an application from Eli Lilly that’s been held up by questions about the design of clinical trials and safety risks.
Why it matters: Their conclusions could influence how the FDA treats future drugs that target proteins in the brain known as amyloid plaques that are believed to contribute to the development of the dreaded neurological condition that afflicts nearly 7 million people in the U.S.
State of play: Lilly’s antibody donanemab was shown to be effective in slowing Alzheimer’s progression by about a third, and it could become the second drug of its kind to receive...
Today's Sponsors
Today's Sponsor